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I. Abstract 
Background: Oxidative stress plays a significant role in the physiological aging process and in some 
pathological conditions, such as Alzheimer’s disease (AD). Studies suggested that biomarkers of 
oxidative and nitrosative stress are elevated in brain of AD patients and that oxidative damage is one 
of the earliest events in AD. In this experimental study, we focused on protein carbonylation and S-
nitrosylation, which are irreversible and reversible post-translational modifications, respectively. The 
aim of this project was to identify protein markers of oxidative stress as an early event in AD 
pathogenesis. We hypothesized first that levels of carbonylated and nitrosylated membrane proteins 
of red blood cell (RBC) – including spectrin –, are increased in patients with cognitive impairment (CI) 
compared to controls, as based on measurements made in human autopsy brain tissue. The CI group 
includes patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Secondly we 
split the CI group in MCI and AD groups, and hypothesized that AD contains less oxidized RBC 
proteins than MCI, supporting the idea that oxidative stress decreases with the disease progression. 
Method: We analysed blood samples from a cohort of one hundred and twenty subjects aged 49 to 
85 years, including 69 cognitive impairment (CI) subjects and 51 age-matched controls. The CI group 
was composed of MCI and AD patients. RBC membrane proteins were extracted and separated by 
one-dimensional electrophoresis. Fluorescent detection was then performed by using anti-
dinitrophenyl (DNP) and anti-S-nitrocysteine antibodies to detect carbonylated and S-nitrosylated 
proteins, respectively. Then we quantified total RBC-membrane protein content and RBC-spectrin 
proteins, as well as their oxidation levels. Finally, we compared the levels of oxidation in CI and 
control groups. Further comparisons were performed in groups with/without established molecular 
biomarkers of AD risk, i.e. increased p-tau/A1-42 ratio in cerebrospinal fluid (CSF) and APOE4 allele 
carriers. Two-dimensional gel-electrophoresis of selected RBC-membrane extracts was performed to 
test for differences in protein content and oxidation.  
Results: The data revealed that protein carbonylation and S-nitrosylation were significantly 
decreased in cases of CI, as determined by a clinical dementia rate (CDR) score compared to controls. 
Oxidized and nitrosylated proteins also tended to decrease significantly in the group with 
pathological p-tau/A1-42 ratio. Finally, S-nitrosylated  spectrin was found decreased in APOE4 
carriers when compared to APOE4 non-carriers. Two-dimensional gel-electrophoresis of selected 
RBC-membrane extracts revealed the presence of heatshock protein 27 (hsp27) and an elongation 
factor 2 (EF2) in CI samples. 
Conclusion: The results showed that the blood of CI patients contained less oxidized proteins than 
controls. This discovery might suggest that oxidative stress has a role in the beginning or before the 
dementia development, and suggests an activation of stress response in the blood, possibly by 
activation of heatshock proteins. Oxidative damages in blood are not accumulated as it was found in 
autopsy brain tissue, but may be eliminated due to the RBC turnover and microvesiculation process, 
thus decreasing the levels of marker proteins. The relation between oxidative stress in blood and AD 
should be more studied by measuring the capacity of antioxidant mechanisms and following the 
progression of the oxidative protein pattern in the same patients. Such an understanding may be 
necessary in order to develop the diagnostic tools to evaluate the role of redox mechanisms in 
peripheral tissues as well as for targeting and designing antioxidant therapies. 
Key Words: Alzheimer’s disease, oxidation, blood, spectrin, marker protein 
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II. Introduction 
a. Alzheimer’s disease 
Epidemiology and clinic 
According to the World Health Organization (WHO) Alzheimer’s disease (AD) is the most common 
form of dementia [2, 19], counting about 2/3 of dementia cases [22, 50]. The other cases include 
fronto-temporal dementia, vascular dementia, dementia with Lewy bodies, Parkinson’s disease, 
Huntington’s disease, etc. Dementia diagnostic is based on CIM-10 classification [22, 50]. Its 
prevalence worldwide is as high as 24 million and it’s predicted to rise due to the population ageing 
[2, 19]. It affects about 0.5% of population aged 65 years and 8 % of population aged 85 years. [22, 
50]. The incidence rate increases exponentially with age and the peak incidence is between 70 and 
80 years old. [22] Therefore dementia will become a growing public-health problem. In brief, this 
neurodegenerative disease related to age consists in a deterioration of memory, other cognitive 
domains and behaviour [2, 22] with a life span between three and nine years after diagnosis [2]. 
AD is divided into two subsets according to the age of onset. First an early onset form (< 65 y/o), 
which has a hereditary background and is generally associated with a more rapid disease decline and 
a Mendelian pattern of inheritance. Secondly, a late onset form (≥ 65 y/o), which is more frequent 
and is the sporadic form [15, 50].  
The first symptoms of AD are usually a deficit of short-term memory and mild confusion, followed by 
a progressive decline of the memory and the other cognitive functions, including temporo-spatial 
disorientation, aphasia, apraxia and agnosia. Moreover, the patient can suffer from executive 
function disorders and neuropsychiatric symptoms [3, 34, 50]. These functions are evaluated with 
medical history, clinical examination and neuropsychological tests, such as the mini mental state 
examination (MMSE) [22]. 
Diagnostic criteria 
The NINCDS-ADRDA Alzheimer's Criteria were proposed in 1984 by the National Institute of 
Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and 
Related Disorders Association (ADRDA). They assign the diagnosis of possible, probable and definite 
Alzheimer’s disease [10]. These diagnostic criteria are based on clinical examination and 
neuropathological features. Not only specific criteria have to be present, but also diseases than can 
cause similar cognitive impairment have to be excluded. Therefore we have to exclude neurological, 
neuropsychological and systemic diseases, as well as delirium and major depressive disorder [50]. We 
must be aware that the definite diagnosis is obtained only by a post-mortem histological examination 
[10]. 
We have to mention a state between normal cognition and dementia, which has been defined as 
mild cognitive impairment (MCI). This group of people doesn’t suffer from dementia, but is at risk of 
developing AD [22]. For more details, conversion from MCI to AD category is based on clinical criteria 
only, and not on valid biomarkers. Recent findings have shown that conversion from MCI to AD 
dementia can be predicted by cued measures, such as the Clinical Dementia Rating scale (CDR) score 
[53] and the CDR scale sum of boxes (CDRSOB) [39]. Furthermore, CDR score and CDRSOB 
demonstrated good reliability to stage dementia severity [39]. The proposed guidelines for CDRSOB 
use suggest that cognitive impairment begins with CDRSOB = 0.5, mild AD with 4.5 ≤ CDR score ≤  9.0, 
mild AD with 9.0 ≤ CDR score ≤ 15.5, and severe AD with 15.5 ≤ CDR score  ≤ 18.0 [42].  
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Biomarkers and neuroimaging 
Biomarkers of Alzheimer’s disease are useful to determine disease risk and to increase the specificity 
of diagnosis. They include measurements from cerebrospinal fluid (CSF) and blood. The accurate 
biomarkers in the cerebrospinal fluid for predicting incipient mild AD are the elevated levels of p-
tau181 and total tau protein, as well as the diminution of the level of A42 [2, 60]. Therefore increased 
p-tau181/A42 ratio is considered pathologic and specific for AD diagnosis [59, 60]. Furthermore it is 
recommended in differential diagnosis of AD. Concerning APOE genotyping, it is not recommended 
as a routine screening [43]. 
Besides these CSF biomarkers, we have other useful tools as predictor of AD occurrence. These tools 
include magnetic resonance imaging (MRI) as structural imaging and positron emission tomography 
(PET) scan or single-photon emission computerized tomography (SPECT) scan as functional imaging. 
Structural and functional neuroimaging studies showed a cortical volume loss predominantly in the 
temporo-parietal cortex and limbic regions – the hippocampus and the amygdala [15, 49, 50]. While 
structural MRI can show brain atrophy in typical regions (Figure 1), functional MRI can show a 
decrease in blood flow. A decreased metabolism and protein aggregates can be observed in 
PET/SPECT scan before visible brain injuries in structural imaging (Figure 2) [22]. 
 
 
 
Figure 1. Brain structural MRI in Alzheimer’s 
patient. The MRI in 2001 (right) shows a 
progressive cortical atrophy in the left temporal 
region, compared to the MRI in 1998 (left) in the 
same patient with AD [61]. http://www.jle.com  
 
 
Figure 2. Brain 18F-FDG PET of a patient with 
Alzheimer's disease (at the bottom) compared 
to structural MRI (on the top). 18F-FDG is a 
marker for the uptake of glucose by a tissue and 
reflects tissue metabolism. This PET shows a 
typical reduced metabolism of the brain 
compatible with mild AD, while the MRI doesn’t 
show yet any cortical atrophy. 
Physiopathology 
Concerning molecular lesions in the aging brain, it has been discovered an accumulation of misfolded 
proteins which results in inflammatory and oxidative damages. It has been established that an 
imbalance between production and clearance leads to proteins aggregation, which can be 
deleterious for neuronal cells [2]. Histopathological hallmarks of AD are characterized by extracellular 
-amyloid (A) deposition, intracellular neurofibrillary tangles (NFT) and neuronal loss [3, 50]. The 
neuronal loss affects particularly the limbic system and the associative neocortex [50]. The -amyloid 
accumulation forms amyloid senile plaques extracellularly. The principal isoform in brain is -amyloid 
42 (A42). This supports the amyloid hypothesis, which suggests that -amyloid is toxic to cells and 
may be one of the initiating factors in AD. The other pathological accumulation – the NFT – is formed 
by an insoluble hyper-phosphorylated tau protein (p-tau), which is a microtubule-associated protein, 
particularly the isoform 181 (phosphorylated at threonine 181). These inclusions are found in 
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pyramidal neurons, contrary to the extracellular deposits of -amyloid [2]. Other pathological 
conditions where protein tau is hyper-phosphorylated include tauopathies, such as Huntington’s 
disease, frontotemporal dementia, etc. [50]. Braak et al. [48] have established in 1991 a 
neuropathological staging of AD according to the distribution pattern of neurofibrillary tangles (See 
the resume in Figure 3). Then increase in p-tau/A42 ratio has been established as a signature to AD 
and is assumed to happen before cognitive impairment. The decreases in -amyloid is due to 
abnormal processing of the peptide, leading to amyloid aggregation in brain and thereby neuronal 
loss. On the other hand, the elevation in tau protein reflects also neuronal loss and brain injury [42].  
 
 
 
 
 
 
Figure 3. Distribution of neurofibrillary tangles. The accumulation of protein tau in AD begins in the temporal region with 
molecular lesions in the entorhinal and transentorhinal cortex (stages I-II). Then the limbic system is affected, including the 
hippocampus and the amygdala (stages III-IV). In advanced stage of disease, the neocortex is involved (stages V-VI). 
http://www.unil.ch  Course of Prof. J. F. Démonet, department of Neurology, Lausanne – CHUV. 
Risk Factors of Alzheimer’s disease 
There are genetic and non-genetic risk factors. Epidemiological studies indicate that less than 10% of 
AD patients have autosomal dominant inheritance, which is related to the early onset of AD [3]. 
Concerning this inheritance, three genes are known to be involved, including amyloid precursor 
protein (APP) and presenilin 1 and 2 (PSEN 1 and 2) genes. These two latter are involved in the 
breakdown of APP generating excess of A, and leading to amyloid aggregation and plaques 
formation [19, 41]. In contrary, sporadic Alzheimer’s disease – the late onset form – is related to 
environmental factors and variations in multiple genes. Researchers have established that the APOE 
gene is susceptible of increasing the risk of sporadic AD. This gene leads to the production of 
apolipoprotein E, which has a role in the transport of lipids in the CSF and to the neurons. Moreover 
there are three major variants, namely APOE2, APOE3 and APOE4 alleles. It has been revealed 
that the APOE4 allele is the major risk factor for AD and that homozygotes have greater risk than 
heterozygotes. Finally people with this APOE polymorphism inherit the risk of developing Alzheimer’s 
disease and not the disease itself. 
Apart from age as the main risk of cognitive decline [2], a lot of non-genetic risk factors have been 
identified. These factors involve cardiovascular disease, cerebrovascular disease, traumatic brain 
injury, smoking, pollutants, dietary protein, type II diabetes, elevated blood pressure, low and high 
body weight, etc. They can induce cerebrovascular lesions by oxidative stress and Adeposition, 
increasing the risk of dementia and AD [15, 22, 63].  
Treatment and protective factors 
Nowadays there is no curative treatment available [3], but there are two classes of pharmacological 
treatments that are indicated in AD to slow down memory impairment. The first class are the 
cholinesterase inhibitors – donepezil, rivastigmine and galantamine – which increase the 
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acetylcholine neurotransmitter and are given to mild AD patients (MMSE 10-26). The second class of 
drugs are the NMDA receptor antagonists – the memantine – which target the glutamate 
neurotransmitter and are indicated for severe AD patients (MMSE 3-19) [3, 4, 50].  
As protective factors we know that physical activity can promote brain vascularization and is 
suggested to protect against the onset and the progression of age-associated dementia [3, 10, 15]. 
Furthermore, some rodent studies have indicated that physical activity decreased the rate of amyloid 
plaque formation in brain and had anti-oxidant effects by increasing superoxide-dismutase (SOD) and 
heat shock protein 70 (Hsp70) [6, 22]. We can also mention the Mediterranean diet characterized by 
nutrients with anti-inflammatory and antioxidant effects, including plant foods, fish, olive oil and low 
intake of red meat (saturated fats) [9, 15, 22]. Finally randomized controlled trials suggested that 
cognitive activities, even in late life, have a role in decreasing the risk to develop dementia [11, 22]. 
Concerning the dietary therapies, prospective assessments found that intake of fruit and vegetable in 
healthy elderly was associated with an improved antioxidant status, lower level of OS biomarkers and 
less cognitive decline in comparison to subjects with poor fruit and vegetable consumption [5, 7, 8]. 
Research projects suggested that moderate intake of unsaturated fats (omega-3 fatty acids), -
carotene, vitamin E, C, B12 and B9 may lower the risk of AD and improve cognitive performance by 
influencing plasticity synaptic [3, 4, 9, 50]. More specifically, the effect of high-dose vit E has been 
studied in a randomized double-blind placebo-controlled study and has shown significant delay on 
loss of ability to perform basic activities and severe dementia [18]. In vitro studies suggest that vit E 
reduces lipid peroxidation and apoptosis linked with A deposition [22]. After all, the use of more 
than a single molecule could be better to reach a therapeutic effect. For instance, it is known that vit 
C is necessary to reduce the vit E radical (oxidized) to the antioxidant form [18, 23]. However we 
have to keep in mind that several research projects didn’t find any association between nutrition and 
cognitive change [9]. In future, the relation between anti-oxidative nutrition and AD might be 
confirmed by long-term placebo-controlled studies to find effective dietary therapies. 
b. Oxidative stress hypothesis 
Free radical reactions are ubiquitous and are supposed to be implicated in the aging process. The 
free radical theory of aging was proposed in 1954 by Harman [23] and postulates, among others, that 
the life expectancy can be extended by decreasing the rate of free radicals [18, 23].  
Metabolic processes that produce reactive particles are oxidation, S-nitrosylation, s-glutathionylation 
and lipid peroxidation [15, 23, 24]. These particles, such as reactive oxygen species (ROS) and 
reactive nitrogen species (RNS), are formed during normal metabolic reactions and have a 
physiological role is the regulation of intracellular signalling [15, 23, 24]. However these instable by-
products are highly reactive and can damage different molecules and may lead to cell dysfunction or 
cell death [15, 19].  To protect from oxidative damages, the body developed defense mechanisms. 
These antioxidant mechanisms decreased with aging, which results in a loss of balance between the 
antioxidant and the reactive species levels. Therefore ROS are produced in excess, which induces 
cellular and mitochondrial damages [15, 18, 23]. The antioxidant system includes the following 
entities: an endogenous antioxidant, namely the glutathione (GSH); enzymes such as glutathione 
reductase and peroxidase, superoxide dismutase (SOD), catalase, thioredoxin peroxidase, 
peroxiredoxins, etc.; antioxidants from diet including tocopherols (vitamin E), the antioxidant -
carotene, ascorbic acid (vitamin C) and retinol (vitamin A); metal ions and cofactors. For example 
Mg2+, Zn2+, NADH, uric acid, etc.; metal-binding proteins such as ferritin, transferrin and 
ceruloplasmin [15, 17]. In addition, chaperons, ubiquitin and proteasome normally prevent misfolded 
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and damaged proteins from aggregating, avoiding cellular impaired function [26]. We can suppose 
that the tendency for proteins to become misfolded and damaged with age is linked to an increased 
oxidative stress and a decreased function of defense systems. 
In medicine, oxidation plays an important role in some human diseases such as Alzheimer’s disease, 
Parkinson’s disease, diabetes, cancer, inflammatory bowel disease, etc. Although the relationship 
between oxidative stress and these diseases remains uncertain, high levels of oxidised proteins have 
been observed in these pathological conditions [17, 35, 37]. The oxidative stress hypothesis 
implicated in the pathogenesis of AD is based on the damages caused by the by-products of oxidative 
and nitrosative metabolic reactions [18, 23, 24]. Several post-mortem human studies have identified 
an increased level of biomarkers of oxidative stress in AD brains compared to controls.  More 
precisely, the by-products are elevated in the fronto-temporal cortex and hippocampus, which are 
typical regions with AD molecular lesions [18]. These different biomarkers include lipid peroxidation, 
DNA/RNA oxidation and protein oxidation (i.e. carbonylation and nitrosylation) [18, 23, 34, 35, 56].  
There is scientific controversy whether oxidative stress in the central nervous system occurs at an 
early stage of Alzheimer’s disease, contributing to its development [1, 2, 26], or whether it results 
from histopathological changes described previously [18]. However, experimental models have 
shown that markers of oxidative/nitrosative stress precede the onset of histopathological changes [1, 
51] and it has been found in human brain that an increase in -amyloid deposition during the 
progression of dementia is associated with decreased oxidative damage [1]. Apparently oxidative 
damage to protein is an early event in AD pathogenesis, which means it is more important at the 
beginning of disease and decreases with the progression of the neuronal lesions [2, 26]. Therefore, 
on the basis of previous studies on experimental models, we supposed that increased OS might have 
a role in accelerating the accumulation of amyloid and tau proteins and it decreases with time. 
Protein modifications 
ROS and by-products of OS can induce reversible and irreversible protein modifications. Protein 
reversible alterations, such as S-nitrosylation, may have a harmless role of modulation of protein 
function, contrary to irreversible protein modifications, such as carbonylation, which can lead to 
protein dysfunction, inactivation and accumulation. Some protein aggregates in brain tissue are 
associated with neurodegenerative diseases, such as Parkinson’s disease and Alzheimer’s diseases 
[26]. A lot of oxidized proteins in AD brain have been found, including cytoskeletal proteins, proteins 
belonging to the ubiquitin-proteasome system (UPS) and other types [ 13, 16, 19]. The cytoskeletal 
proteins identified in carbonylated and nitrosylated states were spectrins, actins, tubulins, glial 
fibrillary proteins and other neurofilament proteins [16, 17, 35, 36, 37, 38, 57]. 
We mention first the cysteine modifications because of its role in the misfolding and function of 
proteins. There are a subset of protein thiols (R-Cysteine-SH), which may exist as reactive thiolate 
anions (R-Cys-S-), that are more readily oxidised by ROS and RNS [17]. This reaction between reactive 
cysteine thiols and nitrogen species is named S-nitrosylation (Figure 4). Furthermore it is a reversible 
post-translational protein modification, leading to a covalent bond, and it regulates the activity of 
many targets. S-nitrosylation plays a dynamic role in neuronal signal transduction and its 
dysregulation has been associated with a variety of pathological conditions, including our disease of 
interest, Alzheimer’s disease [20, 25].  
 
 
SH + RNS = 
Reduced 
protein 
S-nitrosylated 
protein 
Reactive 
nitrogen species 
Figure 4. Cysteine thiol nitrosylation by reactive 
nitrogen species (RNS). The S-nitrosylated protein is 
referred to as a SNO-protein. 
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On the other side we focused our project on carbonylation of proteins, which is the most widely used 
biomarker for oxidative damage. Unlike S-nitrosylation, carbonylation of proteins is a non-enzymatic 
and irreversible modification. The introduction of carbonyl groups (ketones and aldehydes) into 
proteins can be triggered directly by ROS or by-products of oxidative stress, just as S-nitrosylation. 
This irreversible reaction alter the protein conformation and leads to a protein dysfunction or 
inactivation. If the cell is unable to repair or degrade theses protein carbonyls, it can be deleterious. 
It has been suggested that carbonylation targets the modified proteins in order to be eliminated by 
the proteasome system. However, excessive oxidation leads to heavily carbonylated proteins, which 
are resistant to proteolytic degradation by the proteasome. These aggregates in human tissues 
become toxic species and are associated with some neurodegenerative diseases (e.g., amyloid 
precursor protein in AD) [26, 35]. What is more, elevated levels of protein carbonyls have already 
been observed in the brain of persons with mild cognitive impairment and AD patients [37, 58].  
 
 
 
 
 
 
 
 
 
Figure 5. Pathogenic cascade of carbonylation. Irreversible protein carbonylation leading to protein aggregates and 
neurodegenerative disease, in case where the chaperones and the ubiquitin-proteasome system (UPS) didn’t eliminate the 
carbonylated proteins. 
c. Role of the erythrocyte spectrin 
Several studies showed a role of brain spectrin in Alzheimer’s disease. In our lab, Zeinab El Hajj, PhD 
student, has shown that brain spectrin was more carbonylated and nitrosylated in AD and MCI 
subjects in comparison to controls. In addition, it has been reported that the  spectrin is an integral 
component of -amyloid plaques in some sporadic AD cases, supporting the hypothesis that an 
abnormality of spectrin may play a role in the pathogenesis of AD [38]. The spectrin in the RBC 
membrane cytoskeleton has the same role of maintenance of membrane integrity and the same 
structure as the spectrin in neuronal membrane cytoskeleton [38]. For these reasons, we are 
interested in red blood cell spectrin as a biomarker of AD. 
The composition of the RBC-membrane includes a lipid bilayer, transmembrane proteins, and a 
filamentous meshwork forming the membrane cytoskeleton [27, 28, 29, 30, 31] as shown in Figure 6. 
The erythrocyte membrane proteins are divided into two parts as following: firstly, the 
transmembrane proteins, which penetrate the hydrophobic lipid bilayer. The main protein is band 3 
(the anion exchanger) which serves as anchoring site for the membrane skeleton. Glycophorin C also 
serves as a binding site; secondly, the peripheral membrane proteins, which interact with other 
molecules at the membrane surface. These proteins are mainly skeletal proteins such as spectrin, 
Protein carbonylation 
Heavily oxidised proteins 
accumulate in brain tissue 
Degradation by the UPS 
NO DISEASE Cell dysfunction or death 
Neurodegenerative disease 
Protein dysfunction 
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Figure 6. Simplified schema of RBC-membrane structure. The 
membrane skeleton is attached to the transmembrane proteins 
at two sites: 1) by ankyrin, which links the  spectrin to band 3; 
2) by protein 4.1, which binds spectrin, a junctional complex (F-
actin, dematin, tropomodulin, tropomyosin and adducin) and 
glycophorin C. 
actin and proteins 4.1. These latter are responsible for maintaining the cellular shape and structural 
integrity of the membrane. Concerning our protein of interest – the spectrin –, it is a tetramer of two 
 and two subunits. It has an important role in the stability of surface membrane proteins and in 
RBC deformability [31]. 
 
RBC-membrane proteins have been studied for years by polyacrylamide gel electrophoresis [27, 31]. 
In this project, we identified our protein bands in 1-DE gels with the help of the PhD thesis of Dr. 
Julien Delobel (laboratory of the Regional Blood Transfusion Service in Epalinges, Vaud), who 
analysed the RBC-membrane proteins by LC-MS/MS. Some of the validated proteins are indicated on 
the Coomassie blue stained-gel in Figure 7.  
The relation between oxidative stress and red blood cell in neurodegenerative disease has already 
been studied. Scientists compared erythrocytes from AD subjects with erythrocytes from healthy 
donors, and concluded that erythrocyte aging process, characterized by the appearance of IgG, is 
disturbed in Alzheimer’s patients [32]. In other research projects, RBC morphology in AD subjects was 
altered as compared to their age-matched controls. Changes in the level of membrane and 
cytoskeletal proteins were linked to the alteration of RBC morphology in AD subjects [33]. 
Interestingly, S-nitrosylation of RBC-cytoskeleton proteins, especially  and  spectrins, has been 
linked to the improvement in RBC deformability, which is linked to the structural and functional 
integrity of the RBC cytoskeleton [25]. These discoveries encourage us the development of diagnostic 
tools in blood, especially changes in RBC-membrane proteins.  
 
spectrin 
Band 3 
Actin 
Dematin 
spectrin 
Ankyrin 
Protein 4.1 
Tropomyosin, 
band 7 (stomatin) 
Tropomodulin 
Adducin 
A         B 
 
Figure 7. Coomassie blue stained-gel after SDS-
PAGE of RBC-membrane extracts. A: membrane 
proteins extract. B: cytoskeletal proteins 
extract. Indicated proteins are placed according 
to RBC analyses of Dr. Julien Delobel, PhD. 
Peroxiredoxin 
G3PD 
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d. Aims of the project 
The finding of oxidative damage in neurodegenerative diseases [17, 35, 37] raises the therapeutic 
possibilities that antioxidants might be useful in slowing the progression of these illnesses [37]. For 
this reason among others, we decided to study the relationship between the levels of oxidative stress 
and mild cognitive impairment or Alzheimer’s disease (the cognitive impairment group). By-products 
of oxidative processes can damage different molecules, such as lipids, DNA, RNA and proteins [15, 
23, 24]. In this project, our analyses are focused on protein modifications, that yield nitrated and 
carbonyl derivatives. Some discoveries support the choice of our target, showing many of oxidized 
proteins in AD brain, including cytoskeletal proteins, proteins belonging to the UPS and other types 
[13, 16, 19]. Furthermore, studies interestingly demonstrated that cytoskeletal proteins were in 
carbonylated and nitrosylated states; spectrins, actins, tubulins, glial fibrillary proteins and other 
neurofilament proteins were identified [16, 17, 26, 35, 36, 37, 38, 57]. We choose to analyse the 
spectrin in the RBC-membrane cytoskeleton because it has almost the same role and structure as the 
spectrin in neuronal membrane cytoskeleton [29]. We compared the state of carbonylation and 
nitrosylation of total red blood cell membrane proteins – as well as  and  spectrin– in controls, MCI 
and AD (CI group). We also compared the state of oxidation with other variables of AD diagnostic, 
such as p-tau181/A42 ratio and APOE4 genotyping. 
In practice, we extracted membrane and cytoskeletal proteins from whole blood of 120 subjects. 
After the extraction we analysed the RBC-membrane and cytoskeleton by one- and two-dimensional 
electrophoresis, followed by either a Coomassie blue and silver nitrate staining or immunoblot. For 
immunoblotting technique, we used primary antibodies against carbonylation and S-nitrosylation 
modification. The selected antibodies were anti-DNP and anti-S-nitrocysteine, which have been used 
a lot of times in Riederer’s laboratory [12, 16]. Finally an infrared detection was performed to 
identify protein modifications. 
On the basis of several studies cited before [1, 2, 26, 51], we supposed firstly that the CI group might 
have a more important oxidative level compared to controls. Secondly we hypothesized that 
increased oxidative stress could be an early event in cognitive impairment, supposed to be related to 
the accelerated aging process in AD and the accumulation of -amyloid and p-tau, and finally 
decreasing with the progression of the disease.  
In conclusion, for most neurodegenerative disorders, diagnostic tools and biomarkers to reliably 
identify the first signs of disease are still missing [3]. With this project, the OS as an early event in AD 
pathogenesis is not clearly observed, since MCI and AD are firstly considered as one same group. 
Nevertheless we would like to contribute to the development of a reliable protocol to identify 
biomarkers of oxidative stress in Alzheimer’s disease, and later, develop diagnostic tools in peripheral 
tissues. In future, the oxidative stress hypothesis could help to develop optimal nutrition or other 
antioxidant therapies to increase the defense mechanisms against protein aggregate-related 
diseases. 
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III. Materials and methods 
a. Subjects 
The cohort of subjects is currently analysed in a separate study on inflammatory markers conducted 
by the Neuropsychiatry and Biomarkers research group of University Service of Advanced Age 
Psychiatry (SUPAA). This study was approved by the Cantonal Human Research Ethics Commission of 
Vaud (CER-VD). All participants gave written informed consent for the blood and cerebrospinal fluid 
analysis. The cohort contained one hundred and twenty patients aged 49 to 85 years, including 69 
subjects with various levels of cognitive impairment (CI) and 51 healthy age-matched controls. 
The inclusion and exclusion criteria were based on the neuropsychological tests, the Lawton 
Instrumental Activities of Daily living (IADL) [47] and the Clinical Dementia Rating Scale (CDR) [53] 
score. Concerning the neuropsychological examination, the major cognitive domains were evaluated, 
such as memory, language, attention and executive functioning. This latter assessment consisted of 
the Mini Mental State Examination (MMSE) [52], the Buschke Double Memory Test [54], the digit 
span task [45], the Stroop Test [Stroop J.R., 1935], the letter fluency task [46] and the Trail Making 
Tests A and B [55]. 
First of all, the participants in the CI group have been recruited among outpatients with cognitive 
impairment referred to the Memory Centre, University Hospital of Lausanne (CHUV). For their 
inclusion into the study, subjects underwent a collection of medical history as well as 
neuropsychological and clinical examination. The patients scoring ≤ 1.5 SD below gender-, age- and 
education-adjusted norms in the verbal memory tasks, together with a CDR score = 0.5 or = 1, were 
considered to have memory impairment; AD patients have not been differentiated from MCI 
patients. For the control group, healthy community-dwellers have been recruited by advertisement 
or among spouses of memory clinic patients. These participants had no evidence of cognitive 
impairment and had a CDR score = 0. The exclusion criteria were any kind of neurological or 
psychiatric diseases, as well as severe or unstable medical illness. 
Biomarkers have been measured in cerebrospinal fluid, such as total tau, p-tau181 and amyloid 1-42. 
For these measurements, CSF samples obtained from the same patients were analyzed with assays 
using ELISA technology (Innogenetics/Fujirebio Europe N.V., Belgium). Furthermore people carrying 
the established genetic risk factor for sporadic AD – the APOE4 allele – were identified by APOE 
genotyping on blood with the LightCycler (Roche Diagnostics, Basel, Switzerland). Finally these 
parameters have been used as variables for our statistical analysis. 
b. Reagents 
The following reagents have been used: nanopurified water (Barnstead, USA), deionised water, 
Na2HPO4 (Merck, Germany), protease inhibitor cocktail (PIC) (Sigma, USA), n-Dodecyl -D-maltoside 
(DDM) (AppliChem GmbH, Germany), Tris-HCl (Sigma, USA), aminocaproic acid (Sigma, USA), EDTA 
(Pharmacia Biotech AB, Sweden), deoxycholate (DC) (Fluka, Switzerland), NaCl (Merck, Denmark), 
bovin serum albumin (BSA) (Sigma, USA), 2-Mercaptoethanol (Sigma, Germany), sodium dodecyl 
sulfate (SDS) (Sigma, Germany), glycérol (Merck, Germany), bromphenol blue (Fluka, Switzerland), 
acrylamide (Merck, Germany), N,N’-Methylenebisacrylamide (Merck, Germany), TEMED (National 
Diagnostics, USA), ammonium persulfate (Sigma, Germany), glycine (Biosolve Chimie, France), 
DeStreak rehydratation olution (GE Healthcare, Sweden), IPG Buffer (GE Healthcare, Sweden), urea 
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(Applichem, Germany), glycerol (Merck, Germany), DTT (Sigma, Germany), Iodoacetamide (Fluka, 
Switzerland), colloidal coomassie blue G-250 stain (National Diagnostics, USA), silver nitrate (Fluka, 
Switzerland), acetic acid (Brenntag, Germany), sodium thiosulfate (Acros, UK), sodium carbonate 
(Acros, UK), formaldehyde (Acros, UK), Tween 20 (Fluka, UK), Triton X-100 (Chemica, Switzerland), 
non-fat dry milk, methanol (Merck, Germany), 2,4-dinitrophenylhydrazine (DNPH) (Cell Biolabs Inc, 
STA-308, USA) and HCl (Merck, Germany). 
c. Preparation of blood samples 
All participants underwent venous punctures, during which 30 ml of whole blood was collected in 
EDTA tubes (Sarstedt, Germany) and stored frozen at -80°C. These punctures were performed 
precisely between 8:30 and 9:30 a.m. after overnight fasting. Blood samples have been thawed once 
for previous analysis, and again for our oxidative stress analysis, which has been carried out in a blind 
fashion.  
First of all, we proceeded to the extraction of erythrocyte membrane proteins. Our protocol was 
established on the basis of the procedures of the Research and Development team at the Regional 
Blood Transfusion Service in Epalinges (SRTS VD). Whole blood samples were thawed and 1.5 ml was 
placed in three volumes of a hypotonic solution containing 10% phosphate-buffered saline (PBS) 
(5mM Na2HPO4, 155 mM NaCl, nanopure water, pH 7.4) and 5 l of protease inhibitor cocktail (PIC) 
during 1 hour at 4°C under agitation. After the hypotonic lysis, the solution was spun down in a rotor 
50.1 at 27’000 rpm (75’000 g) for 30 min at 4°C in order to separate the membrane and cytoplasmic 
contents. The membrane pellet was transferred to 1.5 ml conical tubes (Eppendorf) and centrifuged 
at 13’200 rpm (16’100 g) for 30 min at 4°C. Afterwards, the red blood cell membranes were washed 
in 0.1 x PBS several times to remove soluble haemoglobin from ghost cells.  
The latter part of the membrane extraction consisted in incubating the ghosts with 5 volumes of a 
non-ionic detergent-containing buffer (7.8 mM n-Dodecyl -D-maltoside DDM, 50 mM Tris-HCl, 750 
mM aminocaproic acid, 0.5 mM EDTA, pH 7.0) at 13’200 rpm for 30 min at 4°C. The soluble content, 
which contained the integral membrane proteins, was removed in 1.5 ml tubes. Finally the 
cytoskeleton was extracted by incubation of the remaining pellet with 5 volumes of an ionic 
detergent-containing buffer (1% deoxycholate DC, 50mM Tris-HCl, 150mM NaCl, pH8.1) at 13’200 
rpm for 30 min at 4°C. 
After extraction the protein concentration was determined using the Bradford Protein assay (Bio-
Rad, Germany) with a 0 to 20 g Bovin Serum Albumin (BSA) calibration curve. Then the samples 
were diluted to a concentration of 2mg/ml with 5x SDS mix (15% Tris, 15% 2-Mercaptoethanol, 10% 
Sodium Dodecyl Sulfate SDS, 10% Glycerol, 5% Bromphenol Blue, pH 6.8). After all, proteins were 
denatured at 95°C for 5 minutes and stored at -20°C after adding 0.1 l of PIC.    
d. One and two-dimensional electrophoresis 
Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS-PAGE) consists in separating 
charged molecules in an electric field. Here we have separated the proteins by one- (1-DE) and two-
dimensional (2-DE) gel electrophoresis. The Sodium Dodecyl Sulfate (SDS) is an anionic detergent 
used to denature proteins and cover them with negative charges, allowing not only the protein 
migration toward the anode, but also the separation by molecular mass.  
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Concerning the 1-DE, the polypeptides were separated according to their molecular mass through 
acrylamide gradient gels of 3.6% - 15%. These latter were made of acrylamide solution (39% 
acrylamide, 1% N,N’-Methylenebisacrylamide), separating buffer (9.1% Tris-HCl, 0.2% SDS, pH 8.8), 
stacking buffer (3% Tris-HCl, 0.2% SDS, pH 6.8), TEMED, ammonium persulfate and nanopure water. 
Once the gels have been made, 20 g of membrane and cytoskeleton extracts, defined as DDM and 
DC extracts respectively, were loaded into each well. Then the electrophoresis was run at 140 V for 
approximately 2 hours and 30 minutes in a running buffer (0.3% Tris-HCl, 1.44% Glycine, 0.1% SDS, 
deionised water). 
The 2-DE procedure in our lab has been previously described [14, 16]. In short, the separation of the 
membrane proteins was made by isoelectric focusing (IEF) pH 3-10 in the first dimension and by 
molecular mass in the second dimension. First, ImmobilineTM Dry-Strips (pH 3-10 NL 7 cm length, GE 
Healthcare, Sweden) were rehydrated with 150 g of desalted blood samples in 125 l DeStreak 
solution and 0.5 % IPG Buffer pH 3-11 NL for 16 hours. The first dimension was performed on EttanTM 
IPGPhorTM 3 system (GE Healthcare, Sweden) with the following running conditions: 300 V at 200 
Volt-hours (Vh), from 300 V to 1000 V at 300 Vh, from 1000 V to 5000 V at 4000 Vh and 5000 V at 
1250 Vh. The next step was performed by equilibrating the Dry-Strips in an equilibration buffer (6 M 
Urea, 2 % SDS, 0.375 M Tris-HCl, 20 % Glycerol) with 130 mM DTT for 15 minutes, and then in a 
solution with equilibration buffer and 135 mM iodoacetamide for 15 minutes. For the second 
dimension, mini-gels were prepared (13% acrylamide separating gel, 4 % stacking gel) and placed in a 
running buffer (0.3 % Tris-HCl, 1.44 % Glycine, 0.1% SDS, deionised water). Finally the electrophoresis 
was run for 1 hour 30 minutes at 140 V. 
After electrophoretic separation, gels were either stained – with Coomassie blue or silver nitrate –, or 
the proteins were transferred from the gel to a nitrocellulose membrane (Bio-Rad, Germany) for 
Western blotting. 
e. Coomassie blue staining 
To visualize the general composition of membrane proteins, the gels were incubated in the 
Coomassie blue overnight. The next morning gel was washed with nanopure water until getting 
visible bands. Finally they were scanned with the Magic Scan program.  
For the establishment of our protocol, this step has initially been made in order to adapt the protein 
loading in wells. The loading has to be adequate and equal for all the wells, so we can compare the 
antibody detection after the Western Blot.  
f. Silver nitrate staining 
Silver staining was used for the 2D polyacrylamide gel electrophoresis. This staining increases the 
sensitivity for the detection of the protein bands about 50 times compared to Coomassie blue. 
First, gels were washed for 30 minutes in a solution containing 50% methanol, 10% acetic acid, 
nanopurified water. Secondly they were washed for 15 minutes in 5% methanol. After washing the 
gels 3 x 5 min with deionised water, they were incubated for 2 min with 0.02% sodium thiosulfate. 
After 3 washes of 30 seconds, gels were incubated for 30 min in a solution of 0.2% silver nitrate. Then 
3 rinses of 1 minute were performed and gels were incubated in a development solution (3% sodium 
carbonate, 50 l formaldehyde, 2 ml of solution C) for 5-10 min. Finally, staining reaction was 
stopped in a 1.4 % EDTA solution for 10 min and a last rinse of 10 min was performed. 
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g. Western Blot and Infrared detection 
Western blot is a technique used to detect proteins of interest, which have underwent an 
electrophoresis, an electrotransfer and finally an incubation with specific antibodies and labeled 
secondary antibodies. The electrotransfer consists in a transfer of the proteins from the 
polyacrylamide gel to a 0.45 m nitrocellulose membrane (Bio-Rad, Germany) for 1 hour and 40 
minutes at 90 V. More precisely, the nitrocellulose membrane is placed on the gel, which are both 
put between two filter papers (Dustcher SA, France), and then placed in a transfer buffer (24.9 mM 
Tris-HCl, 191.8 mM Glycine, 20% methanol, 0.01 % SDS, deionised water). Considering the electric 
current for the protein migration, the membrane was oriented towards the anode. 
Riederer et al. demonstrated satisfying results with their Infrared labelling protocol [12, 13, 14]. We 
used this technique to identify carbonylated and nitrosylated proteins, as biomarkers of oxidative 
and nitrosative stress respectively. A direct detection (Figure 8) was used with two secondary 
antibodies labeled with infrared fluorescent dyes, namely IRDye® 800 CW and IRDye® 700 DX 
(Rockland, Gilbertville PA, USA ), followed by a measure of the signal by digital imaging. 
 
 
 
Figure 8. Fluorescent detection method for Western blot. Here we have used 
polyclonal and monoclonal primary antibodies which bind carbonylated and 
S-nitrosylated proteins, as well as -actin. Then we have added labeled 
secondary antibodies directed against the primary antibodies. Finally digital 
imaging revealed directly fluorescent signal. 
Detection of S-nitrosylated proteins 
All steps have been made under agitation and at room temperature. The first step was to block non-
specific binding sites of the antibodies to the nitrocellulose membrane. This latter was blocked with 
5% non-fat dry milk diluted in 1 x PBS – 0.015% Tween-20 (PBST) for at least 30 minutes. Then the 
membrane was washed with PBS and incubated with primary antibodies in 2.5% milk diluted in PBST 
for 1 hour. The following primary antibodies have been used: rabbit polyclonal anti-S-nitrocysteine 
antibody (Abcam n° 50185, Cambridge, UK) with 1:2000 dilution and mouse monoclonal anti--actin 
antibody (Abcam n° 6276, Cambridge, UK) with 1:10 000 dilution.  
After further rinses, secondary antibodies in 2.5% milk diluted in PBST + 0.1% Triton X-100 (to 
minimize background) were added and incubated for 1 hour. As secondary antibodies, we have used 
IRDye 800 CW Goat Polyclonal anti-rabbit antibody (Rockland, Gilbertville PA, USA n° 611-632-122) 
with 1:10 000 dilution and IRDye 700 DX Goat Monoclonal anti-mouse antibody (Rockland, 
Gilbertville PA, USA, n° 611-130-122) with 1:10 000 dilution.  
The last step is the washing of the membrane with PBS. After all, labeled antibodies were detected 
by scanning the membrane with LI-COR Odyssey® CLx Infrared Imaging System (LI-COR Biosciences 
GmbH, Germany). 
Detection of carbonylated proteins 
To detect protein carbonyls, we have used OxySelectTM Potein Carbonyl Immunoblot Kit (Cell Biolabs 
Inc, STA-308, USA) with the rabbit polyclonal anti-Dinitrophenol (DNP) antibody, 1:1000 dilution (Cell 
Biolabs Inc, n° STA-308, USA). The OxiBlot method allows a detection of oxidized proteins, which 
LASER 
IRDye 
Target 
protein 
Primary antibody 
Secondary 
antibody 
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need a conjugation with 2,4-dinitrophenylhydrazine (DNPH) and the use of the anti-DNP antibody as 
seen in Figure 9. This method is widely used and has been largely described [17, 26]. 
Before the immunoblotting, the derivatization of oxidized proteins was performed. Firstly, the 
nitrocellulose membrane was equilibrated in 20% methanol diluted in Tris-buffered saline (TBS) (20 
mM Tris-HCl, 0.15 M NaCl, pH 7.4) for 5 minutes. Secondly, the membrane was washed in 2N HCl for 
5 minutes and was incubated with 1 x DNPH solution for exactly 5 minutes. Finally we have 
proceeded to three rinses with 2N HCl and five last rinses with 50 % methanol diluted in TBS. 
Concerning the immunoblotting, the protocol was the same as for the nitrosylated protein detection, 
apart from the following changes in reagents and antibodies: the PBS and PBST was substituted by 
TBS + 0.05% Tween 20 (TBST) and anti-DNP antibody was used instead of the anti-S-nitrocysteine 
antibody. 
 
 
Figure 9. Schema of derivatization and Western blot of carbonylated proteins. The derivatization consists in replacing the 
carbonyl groups with the DNPH. This step is followed by the immunoblotting using an anti-DNP antibody and a secondary 
antibody labeled with infrared dye. 
h. Protein quantification and statistical analysis 
ImageJ program was used to assess the intensity of immunostaining and therefore to quantify the 
proteins on SDS-PAGE gel bands. The quantification was assessed on whole migration lanes, and then 
on  and  spectrin separately. The values were normalized with a housekeeping protein – the -
actin – and entered in an Excel database.  
Statistical analysis were performed on IBM SPSS Statistics Version 20.0 with a significance level set at 
p-value < 0.05 with the selected 95% confidence intervals. Firstly we used the Student’s t-test with 
Levene’s test for equality of variances to compare binary variables. Three different variables have 
been used, including the global CDR score, p-tau181/A1-42 ratio and APOEpolymorphism. The first 
variable of CDR score permitted to compare control subjects with CDR score = 0 and patients with 
cognitive impairment (CI) with a CDR score ≥ 0.5. Note that the cognitive impairment group included 
both MCI and AD patients. The second variable included a normal p-tau181/A1-42 ratio < 0.07794, 
which has been defined according to previous determined biomarker cut-offs at the Leenards center, 
and an increased p-tau181/A1-42 ratio > 0.07794, which has been considered specifically pathologic 
for AD diagnosis [59, 60, 66]. Finally we compared APOE4 carriers to non-carriers. 
In a second part, our data have been analysed using the one-way analysis of variance (ANOVA) 
followed by the Tukey post-hoc tests for multiple comparisons. Thus we have compared controls, 
mild cognitive impairment and Alzheimer’s disease, using the Clinical Dementia Rating Scale Sum of 
Boxes Score (CDRSOB) to stage dementia severity [39]. Indeed, the proposed guidelines suggest that 
the controls have a score = 0, MCI is associated with a score between 0.5 and 4.5, and mild AD begins 
with a CDRSOB score = 4.5. Please note that we consider MCI and AD as independent groups. 
In a third part, we excluded the control subgroup which had a CDR score equal to zero. Then we 
determined the MCI and AD groups according to the molecular biomarker, p-tau181/A42 ratio, and 
not according to the CDR score as previously. MCI had a p-tau181/A42 ratio below 0.07794 and AD 
greater than 0.07794, which is known to be associated with Alzheimer’s disease [60].   
R=CO      R=DNP               R=DNP    
R=DNP 
+DNPH + anti-DNP + IRDye 
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IV. Results 
a. 1-DE gels: Coomassie blue stain and Western blots 
One hundred and twenty blood samples were prepared to obtain two different extracts of proteins: 
an integral membrane extract (DDM extract) and a cytoskeletal extract (DC extract). Then SDS-PAGE 
was run and gels were stained with Coomassie blue or immunostained with anti-DNP and anti-S-
nitrosylation antibodies (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Red blood cell membrane proteins separated by SDS-PAGE. Panel A includes membrane extracts from a 
representative control subject and panel B includes membrane extracts from a selected CI patient. The control subjects 
have been selected by their CDR score = 0 and the absence of cognitive impairment. The CI patients have a CDR score ≥ 0.5, 
and include both MCI and AD patients. Samples were first separated by 1-DE 3.6 % - 15 % gradient gels with 20 g of 
proteins per well. A Coomassie blue staining was performed for each sample. Then Western blot was made to detect 
carbonylated and nitrosylated proteins with the following primary antibodies: anti-DNP antibody and anti-S-nitrosylation 
antibody. A normalisation was performed with a housekeeping protein – the β-actin. Molecular mass is indicated on the left 
in kDa. Proteins of interest are indicated on the right. DDM: integral membrane fraction. DC: cytoskeletal fraction. Note that 
the peroxiredoxin is lesser carbonylated and nitrosylated in the CI patient, suggesting that peroxiredoxins are more active in 
the CI blood. 
By comparing the Western blots, differences in the composition of RBC-membrane proteins were 
observed between controls and CI subjects. Interestingly,  and  spectrin were lesser carbonylated 
and S-nitrosylated in the CI group compared to the control group. In addition, some immunostained 
proteins detected on the whole migration lanes are quantitatively lesser immunostained in CI group 
(Figure 10). On the contrary, a band of about 50 kDa was more intensely stained in CI patients (Figure 
10). Although, these proteins have not been identified by mass spectrometry (MS) we can make an 
educated guess, (Table 1) by comparing the protein bands with those reported in the literature (PhD 
thesis of Julien Delobel and references [28, 30, 31]). Please observe the difference in carbonylation 
and S-nitrosylation between control and CI samples of a protein of 25kDa (possibly peroxiredoxin), 
suggesting lesser oxidation. 
  ___     __ 
DDM | DC 
 
 ___      __ 
DDM | DC 
 
___      __ 
DDM | DC 
 
Control 
- α-spectrin 
- β-spectrin 
A 
___    ___ 
DDM | DC 
 
___     ___ 
DDM | DC 
 
 ___      __ 
DDM | DC 
 
Cognitive Impairment (CI) 
- α-spectrin 
- β-spectrin 
B 
- Protein 4.2 
- Actin 
- Tropomodulin 
- Protein 4.1 
- Peroxiredoxin 
- Band 3 
- Ankyrin, band 3, spectrin 
degradation products 
- Dematin 
- α-spectrin 
- β-spectrin 
- Tropomyosin 
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Molecular weight of the 
unknown bands (kDa) 
Suspected membrane proteins 
About 150 kDa Ankyrin, band 3, syndeins and spectrin degradation products 
Between 50-75 kDa Protein 4.1 a and b and 4.2 
About 50 kDa Dematin, tropomodulin and actin 
Between 25-37 kDa G3PD, band 7 (stomatin), tropomyosin and glycophorins A, B, C 
About 25 kDa Peroxiredoxin 
Table 1. List of suspected proteins on the different bands of RBC-membrane SDS-PAGE. Bands on SDS-PAGE of RBC-
membrane proteins from CI patients are different from controls. These visible bands have not been analysed by MS, but 
suppositions were made about the corresponding proteins.  
b. 1-DE: Protein quantification and statistics 
The detection levels of protein carbonylation and nitrosylation were illustrated in the following 
graphs (Figure 11 - 14). In addition, total carbonylation and S-nitrosylation were divided by the total 
proteins detected on Coomassie blue stained gels. These four measures were made on the total red 
blood cell membrane extracts (DDM extract), the cytoskeleton extracts (DC extract), and both  
spectrin and  spectrin subunits. 
In the first part, Student’s test with Levene’s test for equality of variances were used. Two groups 
were compared to each other according to three different variables. The 1st variable was defined by 
p-tau181/A1-42 ratio as a negative measure (if < 0.07794) and a positive measure (if > 0.07794) for the 
specific diagnostic of AD. The 2nd variable contained APOE4 carriers, including homozygotes and 
heterozygotes, and non-carriers. The 3rd variable was determined by the global CDR score, which 
defines a CI group – including MCI and AD patients – and a control group. In the second part, One-
Way ANOVA with Post Hoc tests were used to compare three groups, namely Alzheimer’s disease 
(AD) group, mild cognitive impairment (MCI) group and a control group. These variables were 
defined according to the CDRSOB1 scale described before [39]. More precisely, these guidelines 
suggest that controls have a CDRSOB score = 0, MCI has a score between 0.5 and 4.5, and mild AD 
begins with a score = 4.5. In the third part, we excluded the control subgroup (CDR=0) and 
determined the MCI and AD groups according to the molecular biomarker as described previously. 
First we compared MCI and AD by using the Student’s test, and then we compared the three groups 
– controls, MCI and AD subjects – by using one-way ANOVA. In the last part with the help of the 
statistician, we assessed the categorical outcomes with logistic regressions analyses in order to 
consolidate our results and analyse the independence between the groups which have been 
analysed. 
Part I. Comparison of controls and pathological groups defined by biomarkers, genetic and clinical 
dementia score 
CSF Biomarkers: p-tau181/A42 ratio analysed with Student’s test 
The quantification of carbonylated proteins divided by total protein (carbonyl/total) in the integral 
membrane (DDM) and cytoskeletal (DC) extracts was revealed significantly decreased (p-value = 
0.014 and 0.012 respectively) according to p-tau181/A42 ratio. The levels of nitrosylated and 
carbonylated proteins also decreased significantly in the cytoskeletal extract (DC) in the pathological 
p-tau181/A42 ratio (p = 0.04 and 0.021, respectively) (Figure 11 A and B). 
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The relation between oxidised  spectrin and the CSF biomarkers showed significant decreased levels 
of global nitrosylation (p-value = 0.012) and nitrosyl/total (p-value = 0.047) in the pathological p-
tau181/A42 ratio group (Figure 11 C). The same trend was observed between the  spectrin and the 
pathological ratio (p = 0.025 for the S-nitrosylation and p = 0.064 for S-nitrosyl/total) (Figure 11 D). It 
seemed noteworthy that cytoskeleton extracts revealed a more pronounced staining compared to 
the membrane fractions. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Quantification by densitometry and statistical analysis by Student’s test of RBC membrane proteins according 
to the p-tau/A42 ratio. Normal p-tau181/A1-42 ratio has been defined with a value < 0.07794, and pathological p-
tau181/A1-42 ratio with a value > 0.07794, according to previous studies on this cohort at the Leenards Center. Statistical 
significance (p < 0.05) is identified by an asterisk * on the histograms, high significance (p < 0.01) by two asterisks ** and 
decreasing trend (0.05 < p-value < 0.1) by an asterisk between parentheses (*).  
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Genetic risk factor: APOE4 analysed with Student’s test 
No significant differences in the total proteins of RBC (DDM and DC extracts), neither in the  
spectrin were observed between the APOE4 carriers and non-carriers (not shown). In contrast,  
spectrin was significantly less nitrosylated in the group of APOE4 carriers with a p-value = 0.001 
(Figure 12). 
 
 
 
 
 
 
 
 
 
Figure 12. Quantification by densitometry and statistical analysis by Student’s test of RBC membrane proteins according 
to APOE genotype. High statistical significance (p < 0.01) is reported with two asterisks **. 
Clinical dementia rate score analysed with Student’s test 
Significant differences were also observed between the controls and the CI determined by the CDR 
score. First of all, high significant decreased in carbonylated proteins/total in the membrane (DDM) 
and cytoskeletal (DC) extracts were found in the CI group compared to controls, with respectively p = 
0.007 and p =0.009. The carbonylated proteins of RBC were also significantly reduced in the DDM 
and DC extracts (p = 0.024 and p = 0.035). 
Interestingly different protein modifications were found in the two spectrins, which are significantly 
less nitrosylated in the CI group. We have observed a significant decrease in the nitrosylated  and  
spectrins (p = 0.031 and p = 0.005) and a decreasing trend in the nitrosylated spectrins/total (p = 
0.061 and p = 0.071). 
 
 
 
 
 spectrin 
R
e
la
ti
ve
 d
e
n
si
to
m
e
tr
ic
 u
n
it
s 
(r
d
u
) 
APOE4 non-carrier 
 
APOE4 carrier 
 Nitrosylated proteins 
Carbonylated proteins 
Nitrosylated proteins/total protein 
Carbonylated proteins/ total protein 
** 
21 
 
Nitrosylated proteins 
Carbonylated proteins 
Nitrosylated proteins/total protein 
Carbonylated proteins/ total protein 
Total membrane extract (DDM) 
R
e
la
ti
ve
 
d
e
n
si
to
m
e
tr
ic
 
u
n
it
s 
(r
d
u
) 
CI Control 
 
Total cytoskeletal extract (DC) 
R
e
la
ti
ve
 
d
e
n
si
to
m
e
tr
ic
 
u
n
it
s 
(r
d
u
) 
CI 
 
Control 
 
 spectrin 
R
e
la
ti
ve
 
d
e
n
si
to
m
e
tr
ic
 
u
n
it
s 
(r
d
u
) 
CI 
 
Control 
 
 spectrin 
R
e
la
ti
ve
 
d
e
n
si
to
m
e
tr
ic
 
u
n
it
s 
(r
d
u
) 
CI 
 
Control 
 
A) 
C) 
B) 
D) 
** 
** 
* 
* 
(    ) 
** 
* 
* 
(    ) 
* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Quantification by densitometry and statistical analysis by Student’s test of RBC membrane proteins according 
to the clinical dementia rate score. The control subjects have been selected by their CDR score = 0 and the absence of 
cognitive impairment. The CI patients have a CDR score ≥ 0.5, and included both MCI and AD patients. Statistical 
significance (p < 0.05) is reported with an asterisk *, high statistical significance (p < 0.01) with two asterisks ** and 
decreasing trend (0.05 < p < 0.1) by an asterisk between parentheses (*). 
Part II. Comparison of MCI and AD with controls 
Clinical dementia rate sum of boxes score analysed with One-Way ANOVA 
In this second analytical part, we compared control, MCI and AD subjects according to the CDRSOB 
score. The significance level of these analyses was less reached compared to the first analytical part 
with the Student’s t-test due to the lower statistical power of ANOVA test and the new smaller 
groups. First we discovered a significant decrease in carbonyl/total of DDM extract between controls 
and MCI (p = 0.042). A decreasing trend in carbonyl/total and total carbonylation was also observed 
between controls and AD (p = 0.057 and 0.095 respectively). Then the carbonyl/total of the 
cytoskeleton fraction (DC) tended towards a diminution in MCI and AD compared to controls (p = 
0.059 and 0.054, respectively). Furthermore, while total S-nitrosylated  spectrin had a decreasing 
trend in MCI in comparison to controls (p = 0.054), total S-nitrosylated  spectrin was significantly 
decreased (p = 0.008). 
 
 
22 
 
 
 
Figure 14. Quantification by densitometry and statistical analysis by One-Way ANOVA of RBC membrane proteins 
according to the CDRSOB score. Controls have been selected with a CDRSOB score = 0, MCI had a score between 0.5 and 
4.5, and AD had a score between 4.5 and 18. Statistical significance (p < 0.05) is identified by an asterisk * on the 
histograms, high significance (p < 0.01) by two asterisks ** and decreasing trend (0.05 < p < 0.1) by an asterisk between 
parentheses (*).  
Part III. Comparison of MCI and AD 
In the third part, we excluded the controls (CDR=0) and discriminated MCI and AD subjects according 
to the molecular biomarker (p-tau181/A42 ratio < 0.07794 and > 0.07794, respectively). We tried to 
be more specific in our analyses with the restriction, but since the cohort decreased by 120 to 69 
subjects, the significance also decreased and no significant results were obtained between MCI and 
AD subjects (the CI group) (not shown).  
Then we analysed the controls, the MCI group and AD patients with ANOVA and Tukey tests for the 
multiple comparisons. Interestingly, we found globally significant differences between the controls 
and Alzheimer’s disease subjects. In short, global RBC-integral membrane (DDM extract) and 
cytoskeletal (DC extract) proteins in the AD group were significantly less carbonylated than in the 
controls (not shown). In addition,  and  spectrins were found less nitrosylated in the AD group 
compared to the controls (not shown). 
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Part IV. Logistic regression analysis 
In the last part, we assessed the categorical outcomes with logistic regressions analyses in order to 
consolidate our results. The generalized linear models have been used with additional variables 
including age, gender and APOE4. Given that no significance has been found, more statistical 
analyses should be performed. More specifically, hierarchical analysis – which has more statistical 
power – will be preferred to the generalized additive model which has been used. 
c. 1-DE: Summary of results 
Our study’s aim was to establish a protocol to measure biomarkers of oxidative stress in relation with 
neurodegenerative disease. The biomarkers that we chose were the protein modifications, more 
precisely red blood cell proteins in nitrosylated and carbonylated states. Then we compared the 
levels of oxidative stress biomarkers in blood from controls, MCI subjects and AD patients. The 
samples were analysed first by one-dimensional electrophoresis followed by western blot with 
infrared detection. 
Part I. Oxidative levels of pathological groups compared to controls 
 Carbo Carbo/total Nitro Nitro/total 
Pathological 
p-tau181/A42 ratio 
DDM extract  ↓   
DC extract ↓ ↓↓ ↓  
 spectrin   ↓ ↓ 
spectrin   ↓ (↓) 
Pathological 
APOE4 carrier 
DDM extract     
DC extract     
 spectrin     
spectrin   ↓↓  
Pathological 
CDR score (CI 
group) 
DDM extract ↓ ↓↓   
DC extract ↓ ↓↓   
 spectrin   ↓ (↓) 
spectrin   ↓↓ (↓) 
Part II. Oxidative levels of MCI and AD compared to controls 
 Carbo Carbo/total Nitro Nitro/total 
Mild Cognitive 
Impairment 
DDM extract  ↓   
DC extract  (↓)   
 spectrin   (↓)  
spectrin   ↓↓  
Alzheimer’s 
disease 
DDM extract (↓) (↓)   
DC extract  (↓)   
 spectrin     
spectrin     
Part. III. Comparison of MCI and AD defined by p-tau181/A42 ratio 
No significant results were obtained comparing MCI and AD, but AD subjects showed a significant decrease 
of carbonylated proteins in DDM and DC extracts, compared to the controls (CDR = 0). Furthermore, AD 
showed a decrease of nitrosylated  and  spectrins in comparison to the controls. 
Part IV. Logistic regression analysis 
No significant results were found with the generalized linear model including age, gender and APOE4. 
Table 2. Summary table of results. The levels of oxidation in pathological groups were compared to controls and resumed 
in this table. Significant decrease (p < 0.05) in the pathological groups compared to controls is reported with an arrow ↓, 
high significant decrease (p < 0.01)  with two arrows ↓↓ and a decreasing trend (0.05 < p < 0.1) with an arrow between 
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parentheses (↓). Empty cell translate no significance difference between the pathological group and controls. The level of 
carbonylated RBC proteins was abbreviated as “carbo” and divided by the total proteins, reported as “carbo/total”. The 
level of nitrosylated RBC proteins was abbreviated as “nitro” and also divided by the total proteins, reported as 
“nitro/total”. DDM: integral membrane extract. DC: cytoskeletal extract. Note the trend of spectrins to be less nitrosylated 
in pathological groups compared to controls, while DDM and DC extracts have a tendency to be less carbonylated. 
Our first analyses with Student’s test showed mainly significant decrease of carbonylation in the 
group with pathological p-tau181/A42 ratio – which is related to Alzheimer’s disease diagnosis – and 
in the CI group determined by the CDR score. Concerning  and  spectrins in brief, they were 
particularly less nitrosylated in the same groups. In the second part, the results obtained by the One-
Way ANOVA analysis were less significant, but also showed a global decreasing trend of carbonylated 
red blood cell proteins in the MCI group, and even more in the AD group, in comparison to the 
controls. Spectrins were less nitrosylated in the MCI subjects compared to controls subjects.  
In conclusion our results suggested that levels of oxidative and nitrosative stress in blood decrease 
with the progression of the molecular lesions in brain and the decline of cognitive functions. 
d. 2-DE gels: Silver nitrate and Western blot 
Further results were obtained by Irene M. Riederer, who analysed the same RBC-membrane proteins 
by two-dimensional electrophoresis. 2D gels were stained with silver nitrate to see the global 
composition of proteins and were also prepared for Western blot in order to detect carbonylated 
and nitrosylated proteins (Figure 15). On the 2D silver-stained gels, some spots of proteins appeared 
differently in CI subjects and controls; proteins that were present on CI sample were absent in 
control sample, and vice versa. Afterward these proteins were not visible in carbonylated or 
nitrosylated state in Western blot. Four spots were analysed by MALDI-TOF MS in order to identify 
the differences in the composition of proteins.  
We identified degradation products of band 3 anion transport protein on the four chosen spots 
(Figure 15 A and D). Interestingly, we found a heat shock protein of 71 kDa and an elongation factor 
2 of 95 kDa on the spot number 4 in the CI patient (Figure 15 D). We can suppose that it is related to 
the heat shock response and the induction of the repair machinery to decrease the oxidative 
damages. One should do more immunoblotting to identify repetitive and significant differences 
between the two groups. 
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Figure 15. SDS-PAGE of RBC membrane extracts. Proteins were separated by 2-DE 4 % - 13 % gradient gels. Gels were 
stained with silver nitrate (A and D) or immunostained with anti-DNP (B and E) or anti-S-nitrocysteine antibody (C and F). 
The control subjects have been selected by their CDR score = 0 and the absence of cognitive impairment. The CI patients 
had a CDR score ≥ 0.5, and included both MCI and AD patients. One should note that panel A and B show different spots of 
proteins in CI patient and control subject (red circles and arrows). Four spots (1, 2, 3 and 4) have been selected for the 
analysis by MALDI-TOF MS. Degradation products of band 3 were identified on the four spots in control and CI subjects. In 
addition, a heat shock protein (hsp27) and an elongation factor 2 (EF2) were found on the spot n°4 that was lacking in the 
control sample.  
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V. Discussion 
The first aim of our project was to establish a protocol in order to measure oxidation of red blood cell 
proteins. Then our main hypothesis stated that oxidative stress occurs at an early stage of 
Alzheimer’s disease, contributing to AD pathogenesis. This hypothesis was already tested in some 
research projects [1, 2, 26] and we tested it in our project by analysing the oxidative stress in blood 
from controls, MCI and AD patients. Carbonylation and S-nitrosylation of integral membrane and 
cytoskeletal proteins of RBC were selected as biomarkers of OS. They were assessed by 1-DE and 2-
DE, followed by fluorescent immunedetection as described in previous papers [12, 13, 14, 16]. 
We first analysed p-tau181/A42 ratio, the CSF biomarker which reinforces AD diagnosis when it is 
elevated [43, 59]. An increased level of p-tau181 and a decreased level of A42 reflect respectively the 
levels of neurofibrillary tangles and -amyloid deposition in brain tissue [2]. The analyses 
demonstrated that oxidative and nitrosative stress decreased in the group with positive CSF 
biomarker for Alzheimer’s disease (Figure 11). Our results suggest that levels of oxidative stress in 
the erythrocytes decrease with the progression of the molecular lesions in brain. Therefore it 
suggests that oxidative/nitrosative stress occurs early in AD pathogenesis seen as an oxidative stress 
response in peripheral tissue.  Experimental models on transgenic mice have already shown that 
markers of oxidative/nitrosative stress precede the onset of histopathological changes [51]. 
Moreover our results are in accordance with the study in human brain by Akihiko Nunomura et al., 
who found that an increase in A plaques during the progression of AD was associated with a 
decreased level of oxidised nucleoside derived from RNA – another oxidative damage biomarker [1]. 
In conclusion our results concerning the histopathological hallmarks and oxidative damages are in 
accordance with previous papers supporting that oxidative stress levels decrease with progression of 
the neuronal lesions [2, 26]. Secondly we discovered that our results suggest also that levels of 
oxidative stress in blood decrease with the decline of cognitive functions according to the clinical 
features of the CDR and CDRSOB score. For example,  spectrin was found significantly more 
nitrosylated in controls compared to CI patients (both MCI and AD patients) determined by CDR and 
CDRSOB score (Figure 13 and Figure 14 respectively). Thus this trend might support our hypothesis 
suggesting oxidative stress is an early event in AD pathogenesis and decrease with the disease 
progression. However, more precisely, the OS seems to have a role before the establishment of 
cognitive impairment. Thirdly APOE4 allele carriers seemed to have a  spectrin less oxidized 
compared to the non-carriers in our results (Figure 12). This APOE polymorphism is known to be a 
genetic risk factor for Alzheimer’s disease, and several studies demonstrated an association between 
APOE4 and diseases modulated by oxidative stress as related by Laia Jofre-Monseny et al. [67]. They 
provide that APOE4 is associated with an increase in oxidative stress in post-mortem brains of AD 
subjects, which was not directly demonstrated by our discoveries in blood, given that nitrosylated  
spectrin decreased in the presence of APOE4 allele.  
Comparing our results in blood and other recent projects in brain we noticed that the levels of 
oxidative stress biomarkers follow a different pattern. For example, proteins carbonyls have been 
observed at high levels in the brain of MCI and AD patients compared to controls independently of 
APOE genotype [37, 58]. Interestingly, Zeinab El Hajj, PhD student of Riederer’s laboratory has shown 
that brain spectrin was more carbonylated and nitrosylated in frontal cortex of AD and MCI subjects 
in comparison to controls, supporting findings about protein carbonyls in AD brain [18, 37, 38, 58]. 
These findings suggest that brain tissue behaves differently from blood against oxidative damages, 
and we will try to explain these different mechanisms. 
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In a nutshell, studies on brain showed an increasing trend of oxidized proteins, while studies on 
blood demonstrated a decreasing level of oxidative biomarkers in neurodegenerative diseases. To 
explain this different trend of our blood biomarkers compared to the studies in the brain, we can 
suppose that oxidative damages of brain can’t be well repaired or eliminated contrary to RBC 
damages. First of all, the average life span of erythrocytes is 120 days [62], which means that 
damaged membrane proteins are removed within 120 days too. Then, with the decrease in oxidative 
stress levels, the new erythrocytes produced should not contain oxidised proteins any more. Red 
blood cells have the capacity of regeneration, in contrary to the brain, where damages are 
permanent due to the limited capacity of neuronal cells regeneration. But this explanation is not 
sufficient to decrease significantly the oxidative state in the peripheral tissue compared to the 
central nervous system (CNS). First of all, the CNS is very sensitive to the oxidants because of its high 
lipid content, high consumption of oxygen and many oxidative reactions [21, 76]. The brain has his 
defense mechanisms against excessive oxidative stress, such as the blood, but its antioxidant system 
is clearly not sufficient. The antioxidant enzymes in the CNS include the SOD, glutathione peroxidase 
and catalase, and the non-enzymatic system includes vitamins, as well as proteins and amino acids. 
However these endogenous defenses are not sufficient and unfortunately antioxidant enzymes from 
blood do not cross the blood brain barrier (BBB). The BBB, consisting in endothelial cells connected 
by tight junctions, separates the blood from the brain and selects the molecules to pass in order to 
protect the CNS. Water, gazes and some other molecules can pass, but antioxidant enzymes can’t 
pass across the BBB. Thus, the enzymes circulating in blood may not counteract increasing oxidation 
lesions in neurons [75, 76].  
Then we refer to the hypothesis stipulating that the antioxidant defense – enzymatic and non-
enzymatic – increases in response to an increased oxidative/nitrosative stress [21, 23, 70]. Enzymatic 
antioxidant defenses of the human body, such as the glutathione, the superoxide dismutase, the 
catalase and the peroxiredoxin, help to decrease the oxidative damages in blood [15, 17, 69, 70]. The 
peroxiredoxins are antioxidant enzymes which reduce hydrogen peroxide. But when the levels of 
peroxide increase, the peroxiredoxins become overoxidized and their enzymatic activity are reduced, 
generating an elevation in ROS for redox signalling. This inhibition is due to the formation of a sulfinic 
acid (SO2H) by the overoxidation of the peroxidatic cysteine of the peroxiredoxin [69]. As observed in 
Figure 10, peroxiredoxin was less oxidized in the CI patient blood than in controls, suggesting that 
there was more enzymatic activity in the pathological situation, in order to reduce oxidized proteins. 
In the control situation, peroxiredoxins were stronger oxidized, meaning that oxidation was reducing 
enzymatic activity, allowing an oxidative burst. Finally we conclude to an elevation of the antioxidant 
capacity in the CI patient in response to the oxidative stress. It could be interesting to measure the 
levels of the glutathione and peroxiredoxins in the patients’ blood in future, to assess the progression 
of its level with the progression of the disease. Thus we could see if OS is compensated by the 
antioxidant capacity, translating a balanced redox system. 
Besides these antioxidant enzymes, our results of 2-DE gels showed an increase in heat shock protein 
(Hsp) 27 in CI patient’s blood compared to the control (Figure 15). Thus we raised the possibility of 
the heat shock protein increase in pathological conditions, translating an elevation of OS response 
protein in CI patients (including MCI and AD). This response to ROS/RNS has already been observed 
[33]. Its role is to prevent cell dysfunction partly due to misfolded and aggregated proteins. 
Chaperones can induce pathways that lead to stress responses, which help to protect from a stress 
damage. They assist in refolding or degrading the misfolded proteins, in order to stabilize them and 
avoid aggregation [26]. More precisely, the activation of the proteasome is partly due to the Hsp27, 
and permits the degradation of the misfolded and oxidized proteins [71]. When these latter cannot 
be refolded by the chaperones, they are ubiquitinated for degradation by the proteasome. 
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Unfortunately, heavily oxidized proteins inhibit the UPS and cannot be degraded, leading to an 
aggregation and cell injury. Proteasome and chaperones dysfunction occurs in neurodegenerative 
disorders, probably due to the inhibition by oxidative stress [26, 71]. Furthermore heat shock 
proteins have an anti-apoptotic role, by a direct inhibition or by preventing the activation of caspase-
3 [71].  Concerning Hsp27, it is constitutively expressed in the cortex of the brain and it is also 
inducible in glial and neuronal cells in response to stressors, including ischemia, hyperthermia and 
psychological stressors. Interestingly, some studies demonstrated that high serum levels of Hsp27 
was a marker of myocardial ischemia and incipient chronic obstructive pulmonary disease. In 
conclusion, Hsp27 might modulate ROS and have neuroprotective effects. The relation between this 
chaperone protein and Alzheimer’s disease is not well established, but phosphorylated Hsp27 was 
observed before in neurodegenerative diseases and is supposed to counteract the effects of 
oxidative damages in the CNS [71]. This hypothesis is compatible with our results obtained in the 2-
DE gels.  
Furthermore, we identified an additional spot in CI patient which was absent in control subject 
(Figure 15). The identification by MALDI-TOF MS showed an elongation factor 2 (EF2), which is a 
protein substrate of a Ca2+/calmodulin-dependent enzyme, named EF2 kinase. The EF2 is involved in 
protein synthesis and its activity is inhibited when it is phosphorylated by the EF2 kinase. Philippe 
Marin et al. reported that glutamate in neurons – the major excitatory neurotransmitter – enhances 
Ca2+ influx, EF2 kinase activation and EF2 phosphorylation, leading to EF2 inhibition and therefore to 
protein synthesis inhibition. Researchers showed that EF2 kinase was activated in anoxic conditions 
and with overstimulation by glutamate. They discovered that the protein synthesis inhibition 
protected from excitotoxicity and delayed neuronal death [72, 73]. We can suppose then that EF2 
plays a neuroprotection role in Alzheimer’s disease. 
Apart the differences between the brain and the blood, it is important to identify and understand the 
significant differences between normal aging and neurodegenerative diseases. Metabolic processes 
participating in physiological redox signalling produce reactive oxygen/nitrogen species, which are 
known to cause damages when the redox balance is lost [23, 69]. In fact, these damages increase 
with aging and even more in some diseases, while anti-oxidants systems decrease with aging [24]. 
Researchers are still studying the specific and reliable markers in Alzheimer’s disease, comparing 
factors that prime in MCI and AD subjects compared to age-matched controls. Interestingly, although 
carbonylated proteins increase both during normal aging and neurodegenerative diseases, some 
proteins are selectively more oxidized in some diseases. For example, human brain copper-zinc SOD 
has an isoform which is heavily carbonylated in AD subjects compared to a normal aging brain in 
controls [26]. Moreover, some blood and brain biomarkers prime in MCI and AD subjects compared 
to normal aging controls (i.e. not accelerated aging). These studied biomarkers include several 
oxidized proteins, lipid peroxidation and nucleic acids oxidation [17, 18, 21, 23, 34, 35, 37, 56]. In this 
project we choose to study carbonylated and S-nitrosylated red blood cell membrane proteins, which 
have been associated with AD [20, 25, 37, 42]. Interestingly S-nitrosylation of RBC-cytoskeleton has 
been associated with the improvement in RBC deformability [25], which has been reported to be 
significantly decreased in AD subjects by Joy G Mohanty et al., causing some neurodegenerative 
lesions [33]. These discoveries lead us to suppose that nitrosylated proteins of red blood cell 
cytoskeleton decreases with the progression of AD, which is compatible with our results showing a 
decrease in nitrosylated and  spectrins. Concerning the reason of the decrease in carbonylation, 
Julien Delobel, PhD of “Ma Vie Ton Sang laboratory”, hypothesized that oxidative alteration can 
cause a cytoskeleton and membrane destabilization during blood storage. He also found that the 
state of carbonylation decreased in the DDM membrane extract after four weeks of storage. Julien 
Delobel supposed the elimination of the carbonylated proteins by the microvesiculation process, 
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which might be triggered by oxidative damages of RBC-cytoskeleton proteins [68]. This process 
consists in a membrane vesiculation, which releases microparticles, allowing the elimination of 
oxidized membrane and cytoskeletal proteins. This release of vesicles might have a protective role. 
Indeed, studies showed that RBC-membrane vesiculation correlates with spectrin oxidation in stored 
RBCs [70, 74]. This microparticulation is then supposed to be a defense mechanism of red blood cells 
against oxidative damages and could explain our results. In conclusion, nitrosylation and 
carbonylation can dysregulate RBC deformability and function, probably contributing to neuronal 
lesions in neurodegenerative diseases related to oxidative damages.  
VI. Conclusion and outlook 
Alzheimer’s disease is one of the world’s biggest problem due to the important number of people 
affected according to the World Health Organization (WHO). Although the cause is not clearly 
understood, some hypotheses are well established, such as the -amyloid cascade hypothesis [2]. 
Moreover, much data points to a significant role of oxidative stress and inflammation as early events 
in the disease or appearing before cognitive disorder [23, 64]. In order to better understand the 
relation between the levels of oxidative stress and the cognitive impairment in Alzheimer’s disease 
we processed to analyse the red blood cell protein modifications. This method, which gave significant 
results, points to new reliable biomarkers that can be used to set up diagnostic tools to measure 
changes in peripheral tissue in AD or other neurodegenerative diseases. 
The results showed that the blood of MCI and AD patients (CI group) contained lesser oxidized RBC-
proteins than controls. This discovery might suggest that oxidative stress is an early event in 
dementia [26]. In addition, we found that RBC-spectrin is affected by a decrease in S-nitrosylation, 
while the total RBC-membrane proteins are affected by a decrease in their carbonylated state. The 
lesser nitrosylation of spectrins may be correlated with the diminution of RBC deformability, oxygen 
exchange and consequently leading to brain damages [25, 33]. 
The next step will be to apply our protocol in the CSF to assess the trend of the oxidative stress in 
comparison to peripheral blood. Some studies in Julius Popp’s laboratory analysed the inflammation 
biomarkers in CSF and found some significant differences between AD subjects and controls. As we 
know that inflammation and oxidative stress coexist in AD brain [64], we would like to see if OS also 
shows significant differences in oxidation levels in CSF. As concomitant analyses we can keep on with 
the 2-DE gels in order to detect a variance in the total, the carbonylated and the nitrosylated proteins 
in blood between controls, MCI, and AD. Then it would be interesting to perform a longitudinal study 
following the levels of oxidised proteins in relation with the AD progression in order to observe if the 
OS keeps on decreasing, supporting the hypothesis that OS decreases with the cognitive decline. 
Furthermore, the relation between OS in blood and AD should be more studied by measuring the 
capacity of antioxidant mechanisms, although a similar project has already been carried out and 
didn’t find any significant results [65]. To estimate the antioxidant status in the subjects, we can use 
an antioxidant assay kit (Chemie Brunschwig AG, Basel), which measures the total antioxidant 
capacity of plasma and serum. We can also precisely measure the peroxiredoxin level, which 
appeared to be interesting in our results, or even the gene expression of the heat shock proteins. 
Finally the final confirmation would be to have the definite diagnosis of AD and measure oxidative 
stress levels in post-mortem brain tissue.  
This project may be useful to develop diagnostic tools to measure oxidative stress in peripheral 
tissues and lead to a screening test in the future. Then we will probably need to understand better 
how antioxidants can prevent oxidative stress in neurodegenerative diseases in order to find optimal 
30 
 
nutrition or antioxidant therapies for this public-health concern. In conclusion our results allowed us 
to better understand the AD pathogenesis in relation with oxidative stress. 
Study limitations 
We obtained interesting and significant results in our study, however we have to mention some 
limitations of this project. First of all, there is the selection bias of the subjects, because the two main 
groups, namely the CI and control groups, have not been selected in the same way, although they 
were considered independent. As described before, the first group included patients who suffer from 
cognitive complaints and the second group included in part their spouses. Thereby our oxidative 
measures may not be representative of the dwellers-community.  
Moreover, we have to keep in mind that the levels of oxidized proteins in blood are modulated by 
nutrition, exercise training, cognitive activities and diseases [5, 6, 11], thus, may lead to a variability 
of oxidative stress between subjects. Not only this information was not available for a more detailed 
analysis, but also the comorbidities were not controlled and considered having an impact in the 
oxidative parameters. In addition, APOE4 groups have not been separated in heterozygotes and 
homozygotes. Concerning the statistical analysis, we observed a heterogeneity in the analysed 
groups. We considered that the groups were independent, but there are many variables that overlap, 
which lead to a difficult interpretation of our results. Further, we should have a larger cohort in order 
to detect minimal significant differences.  
Finally we developed a new method to measure the levels of oxidative and nitrosative stress in 
blood, but some parameters have to be improved to be sure that our protocol reflects the real 
oxidative status in blood contributing to Alzheimer’s disease. Nevertheless the oxidative stress is not 
AD specific and has been observed in a large panel of diseases, decreasing the chance to develop a 
specific screening test for AD. It is difficult to conclude a real correlation between OS and AD, as well 
it is difficult to understand the relation between clinical aging and molecular lesions. Given that the 
causality is not evident, we can just suppose that OS is related to the accelerated aging in Alzheimer’s 
disease. Even with these limitations, our results followed a significant trend and provide us some 
possibilities for future prevention strategies. 
VII. Abbreviations 
1- and 2-DE = one- and two-dimensional 
electrophoresis 
A42 = isoform 42 of -amyloid 
AD = Alzheimer’s disease 
APOE4 = allele 4 of apolipoprotein E 
BBB = brain blood barrier 
CSF = cerebrospinal fluid 
DC = cytoskeletal membrane extract  
DDM = integral membrane extract 
EF = elongation factor 
Hsp = heat shock protein 
MCI = mild cognitive impairment  
MMSE = mini mental state examination 
MS = mass spectometry 
NFT = neurofibrillary tangles 
OS = oxidative stress 
p-tau = phosphorylated tau protein 
RBC = red blood cell 
SDS-PAGE = Sodium Dodecyl Sulfate 
PolyAcrylamide Gel Electrophoresis 
SOD = superoxide dismutase 
UPS = ubiquitin-proteasome system 
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